Design Pharmaceuticals Closes $5 Million Pre-series A Round to Accelerate Commercialization of ...
- GPCR News
- Apr 1, 2022
- 1 min read
April 2022
Design Pharmaceuticals Closes $5 Million Pre-series A Round to Accelerate Commercialization of Ultrahigh Throughput Drug Discovery Platform
"April 12, 2022 07:00 AM Eastern Daylight Time
CAMBRIDGE, Mass.--Design Pharmaceuticals, a company redesigning small molecule drug discovery, today announced the closing of a pre-series A round of $5 million, including an investment of $3 million from Virtus Inspire Venture Partners. The proceeds will be used to further build the company’s discovery platform and operations. Design Pharmaceuticals’ platform is based on ultrahigh-throughput technologies that biomine drug-like molecules from natural sources, such as microbiota. These molecules are then evaluated at unprecedented speed and scale on hundreds of GPCR targets simultaneously."
Comments